Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Glaukos Corporation (GKOS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the information. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on therapies for glaucoma, corneal disorders, and retinal diseases, and its filings provide detailed insight into this business.
Through periodic reports such as Forms 10-Q and 10-K, investors can review Glaukos’ net sales, segment performance in glaucoma and corneal health, gross margins, operating expenses, and net income or loss. These filings also describe risk factors relevant to its ophthalmic device and pharmaceutical portfolio, including regulatory requirements, clinical trial processes, reimbursement dynamics, manufacturing considerations, and intellectual property matters referenced in the company’s public communications.
Current reports on Form 8-K capture material events such as quarterly and annual financial results, preliminary net sales updates, and investor presentations. For example, Glaukos has filed 8-Ks to furnish press releases on second and third quarter financial results, preliminary unaudited net sales for a fiscal year, and investor presentation materials. These documents often include or reference revenue guidance ranges and explanations of non-GAAP financial measures and constant currency net sales metrics.
On Stock Titan, AI-generated summaries help explain the key points of lengthy filings, highlighting items such as revenue trends, segment details, and notable risk disclosures without replacing the full text. Real-time updates from EDGAR ensure new Glaukos filings appear promptly, while dedicated sections make it straightforward to locate quarterly reports, annual reports, and current reports tied to material announcements.
For users analyzing GKOS, this page offers a structured view of Glaukos’ SEC reporting history alongside AI insights that clarify complex financial and regulatory information related to its ophthalmic pharmaceutical and medical technology activities.
Glaukos Corporation granted director Marc Stapley 727 restricted stock units on 01/02/2026. These units were issued under the company’s Director Compensation Policy, will vest in full one year after the grant date, and will be settled in the same number of Glaukos common shares.
Following this award, Stapley beneficially owns 37,449 shares of Glaukos common stock, which includes 2,835 restricted stock units that have not yet vested or been delivered, as well as vested units whose delivery has been deferred.
Glaukos Corporation's Chief Development Officer reported a routine share withholding related to equity compensation. On 12/30/2025, 510 shares of common stock were withheld by the company at $114.24 per share to cover tax obligations when previously granted restricted stock units vested. After this transaction, the officer beneficially owned 77,451 shares of common stock. This total includes 43,562 restricted stock units that have been granted but have not yet vested or been delivered, meaning they may convert into shares over time if service or other conditions are met.
Glaukos Corporation’s Chairman, CEO and director reported an insider stock transaction dated 12/30/2025. The filing shows that 1,098 shares of common stock were withheld by the company to satisfy the reporting person’s tax withholding obligations when restricted stock units granted on March 24, 2022 vested and were delivered.
After this tax-withholding transaction, the insider beneficially owned 153,775 shares of Glaukos common stock. This total includes 89,621 restricted stock units that have been granted but have not yet vested or been delivered.
Glaukos Corporation’s chairman and CEO reported earning 4,168 shares of common stock tied to a performance-based restricted stock unit award granted on March 24, 2022. The board’s Compensation, Nominating and Governance Committee determined certain operational targets were achieved, so this portion of the award was earned at a reported price of $0 per share.
Half of these 4,168 shares are scheduled to vest and be delivered in March 2026 and the other half in December 2026. Following this transaction, 154,873 shares are beneficially owned directly, including 91,705 restricted stock units that have not yet vested or been delivered, and additional indirect holdings are reported through several Burns family and charitable trusts. The CEO also acquired 8,416 stock options at an exercise price of $55.18 per share from the same 2022 performance award, which will vest 50% in March 2026 and 50% in December 2026 and are part of 86,262 stock options held directly, expiring on March 24, 2032.
Glaukos Corp reported that its President and COO acquired 7,316 stock options on 12/11/2025 under a previously granted award tied to pre-determined operational targets. These options have an exercise price of $55.18 and were earned after the Compensation, Nominating & Governance Committee determined that certain operational targets over a multi-year performance period had been achieved.
The options represent a portion of an award originally granted on March 24, 2022, and will vest in two equal installments, with 50% becoming exercisable in March 2026 and the remaining 50% in December 2026. Following this transaction, the executive beneficially owned 65,013 derivative securities, held directly.
Glaukos Corporation disclosed that its senior vice president and chief financial officer earned 3,660 stock options tied to performance goals. These options, with an exercise price of $55.18 per share, are part of an award originally granted in March 2022 and became earned after the company met specified operational targets.
Half of this earned portion will vest and become exercisable in March 2026, with the remaining half vesting in December 2026. After this update and a de minimis correction of a prior mathematical error, the officer directly holds 37,510 stock options in total.
Glaukos Corporation’s Chief Development Officer reported an equity award update. On December 11, 2025, the officer was credited with 2,054 shares of common stock at a price of $0, tied to a previously granted restricted stock unit (RSU) award from March 24, 2022 that depended on meeting pre-set operational targets over a multi-year period.
The board’s Compensation, Nominating and Governance Committee determined that certain of these targets had been achieved, and this share amount represents the portion of the award earned based on that performance. Half of these shares will vest and be delivered in March 2026, with the remaining half vesting and delivering in December 2026. After this update, the officer beneficially owns 77,961 shares, including 44,589 RSUs that are still unvested.
Glaukos Corp (GKOS) director transaction: On 12/09/2025, a director exercised a stock option to acquire 5,000 shares of common stock at an exercise price of $24.69 per share, then sold 5,000 shares of common stock on the same date at a weighted average price of $107.27 per share across multiple trades.
After these transactions, the director beneficially owns 34,905 shares of Glaukos common stock, which includes 2,569 restricted stock units that have not yet vested or been delivered, as well as vested units with deferred delivery. The director also continues to hold 10,000 stock options with an exercise price of $24.69, originally granted in 2016 and already fully vested.
Glaukos Corporation insider has filed notice of a planned sale of common stock under Rule 144. The seller plans to sell 5,000 shares of Glaukos common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $536,368.18. The filing notes that 57,434,740 shares of Glaukos common stock were outstanding at the time referenced. The shares to be sold were acquired on 12/09/2025 through an option granted on 06/02/2016, with cash as the form of payment. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Glaukos’ current or prospective operations.
GLAUKOS Corp (GKOS) senior executive stock sale disclosed. The company’s Senior Vice President and Chief Financial Officer reported selling 315 shares of common stock on 11/25/2025 at a price of $105 per share. After this transaction, the executive beneficially owns 50,488 shares of GLAUKOS common stock.
The filing notes that these sales were carried out under a Rule 10b5-1 trading plan adopted on June 11, 2025, which is a pre-arranged plan designed to allow insiders to sell stock over time according to set instructions. The reported holdings include 13,751 restricted stock units that have not yet vested or been delivered and 167 stock units acquired through the company’s employee stock purchase plan.